Novel agents and regimens for hematological malignancies: recent updates from 2020 ASH annual meeting

Antibodies and chimeric antigen receptor-engineered T cells (CAR-T) are increasingly used for cancer immunotherapy. Small molecule inhibitors targeting cellular oncoproteins and enzymes such as BCR-ABL, JAK2, Bruton tyrosine kinase, FLT3, BCL-2, IDH1, IDH2, are biomarker-driven chemotherapy-free age...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:J Hematol Oncol
Main Authors: Hou, Jing-Zhou, Ye, Jing Christine, Pu, Jeffrey J., Liu, Hongtao, Ding, Wei, Zheng, Hong, Liu, Delong
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2021
Teme:
Review
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC8059303/
https://ncbi.nlm.nih.gov/pubmed/33879198
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-021-01077-3
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki